Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MNA Analysis: Abbott And Stryker Make Big Deals In Slow Month

This article was originally published in Clinica

Executive Summary

February 2016 was a slow month for medtech mergers and acquisitions punctuated by three billion-dollar-plus deals.

You may also be interested in...



M&A Deals Analysis: February Sees Billion-Dollar Buys Bite

Despite being a slow month, megadeals abounded in February, as the medtech M&A market saw a hat-trick of billion-dollar deals. Medtech Insight recorded 12 deals for the month, on par with January's volume but down from 16 in February 2016.

Start-Up Spotlight: Apama Medical, Targeting AFib With An RF-Balloon Combo

Founded and led by serial entrepreneur Amr Salahieh, Apama Medical is developing a system that aims to combine the advantages of two approaches for treating atrial fibrillation: point-by-point radiofrequency-based ablation and cryoballoon ablation.

No Surprise As Abbott Cuts Loose Angio-Seal, Femoseal To Terumo

Abbott and St. Jude Medical are to lighten their cardiovascular portfolios – and hopefully facilitate the completion of Abbott's pending $25bn acquisition of St. Jude – by selling three product lines to Terumo. Two of the three product lines to be divested come as little surprise, but one product was acquired by Abbott only earlier this year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT103254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel